Complication rates of CT-guided transthoracic lung biopsy: meta-analysis.

Heerink WJ, de Bock GH, de Jonge GJ, Groen HJ, Vliegenthart R, Oudkerk M. · 2017

Read Complication rates of CT-guided transthoracic lung biopsy: meta-analysis. by Heerink WJ, de Bock GH, de Jonge GJ, Groen HJ, Vliegenthart R, Oudkerk M. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5127875.txt.

Introduction

W. J. Heerink, G. H. de Bock, G. J. de Jonge, H. J. M. Groen, R. Vliegenthart, and M. Oudkerk pooled studies of lung biopsy harms in European Radiology, with the hosted text dated 2017. The biopsy, guided by CT scans through the chest wall, samples lung nodules, and the team compared its two needle types.

Across 32 studies of core biopsy covering 8,133 procedures, complications of any kind struck about 39 percent of core biopsies. Across 17 studies of fine needle aspiration covering 4,620 procedures, the rate was about 24 percent. Serious complications stayed low, near 6 and 4 percent. For aspiration, wider needles, smaller nodules, and more lung tissue crossed raised the risk. Minor problems are common, the authors conclude, but major ones are rare for both methods.

Catalog record

CREATORHeerink WJ, de Bock GH, de Jonge GJ, Groen HJ, Vliegenthart R, Oudkerk M.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5127875

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Complication rates of CT-guided transthoracic lung biopsy: meta-analysis By W J Heerink, G H de Bock, G J de Jonge, H J M Groen, R Vliegenthart, M Oudkerk Published in: European Radiology DOI: 10.1007/s00330-016-4357-8 ABSTRACT Abstract Objectives To meta-analyze complication rate in computed tomography (CT)-guided transthoracic lung biopsy and associated risk factors. Methods Four databases were searched from 1/2000 to 8/2015 for studies reporting complications in CT-guided lung biopsy. Overall and major complication rates were pooled and compared between core biopsy and fine needle aspiration (FNA) using the random-effects model. Risk factors for complications in core biopsy and FNA were identified in meta-regression analysis. Results For core biopsy, 32 articles (8,133 procedures) were included and for FNA, 17 (4,620 procedures). Pooled overall complication rates for core biopsy and FNA were 38.8 % (95 % CI: 34.3–43.5 %) and 24.0 % (95 % CI: 18.2–30.8 %), respectively. Major complication rates were 5.7 % (95 % CI: 4.4–7.4 %) and 4.4 % (95 % CI: 2.7–7.0 %), respectively. Overall complication rate was higher for core biopsy compared to FNA (p < 0.001). For FNA, larger needle diameter was a risk factor for overall complications, and increased traversed lung parenchyma and smaller lesion size were risk factors for major complications. For core biopsy, no significant risk factors were identified. Conclusions In CT-guided lung biopsy, minor complications were common and occurred more often in core biopsy than FNA. Major complication rate was low. For FNA, smaller nodule diameter, larger needle diameter and increased traversed lung parenchyma were risk factors for complications. Key Points • Minor complications are common in CT-guided lung biopsy • Major complication rate is low in CT-guided lung biopsy • CT-guided lung biopsy complications occur more often in core biopsy than FNA • Major complication rate is similar in core biopsy and FNA • Risk factors for FNA are larger needle diameter, smaller lesion size Electronic supplementary material The online version of this article (doi:10.1007/s00330-016-4357-8) contains supplementary material, which is available to authorized users. Keywords: Lung neoplasms; Meta-analysis; Biopsy; Pneumothorax; Computed tomography, X-Ray INTRODUCTION In the US, lung cancer screening by low-dose computed tomography (CT) is recommended for people at high risk [1], and the European Society of Radiology and the European Respiratory Society have recently recommended lung cancer screening within clinical trial setting or in routine clinical practice at certified medical centers [2]. This development will cause an increase in CT-detected lung nodules. Nodules >10 mm and most likely even smaller nodules with high growth rate will be eligible for medical work-up, including CT-guided lung biopsy [2]. CT-guided transthoracic lung biopsy is a minimally invasive diagnostic procedure for tissue diagnosis of peripheral lung nodules. This can alternatively be achieved by surgery, but CT-guided transthoracic lung biopsy is less invasive and associated with lower costs. CT-guided transthoracic lung biopsy is a widely accepted procedure [3, 4], although the reported complication rate varies greatly. Where some papers report a higher complication rate for core needle biopsy compared to fine needle aspiration (FNA) [5, 6], other studies [7, 8] do not. Yao et al. [9] concluded in a systematic review comparing FNA with core biopsy that no significant difference in complication rate between these techniques exists. They also concluded that core biopsy is generally reported to have a somewhat higher diagnostic performance compared to FNA, especially in identifying histological subtypes; the evidence is insufficient to support a difference. Complication rate and diagnostic performance are the two main factors in choosing a diagnostic procedure. To determine the role of CT-guided transthoracic lung biopsy in the work-up of screen-detected lung nodules, it is imperative to know how safe the procedure is. We conducted this meta-analysis to 1) determine the complication rate, and 2) identify risk factors for complications of CT-guided core biopsy and FNA. MATERIALS AND METHODS This study was conducted according to the PRISMA guidelines for systematic reviews and meta-analyses [10]. Search strategy and study selection A literature research was performed from January 2000 to August 21, 2015, on PubMed, Embase, Web of Science, and the Cochrane Library using variations of the combination of the following search terms: (biopsy OR FNA) AND (transthoracic OR CT-guided) AND (lung cancer) AND CT. Please see e-Table 1 for the set of search terms per database. After screening title and abstract, two reviewers (W.H., G.J.) evaluated the full text of the remaining articles, with disagreements resolved by consensus. Inclusion criteria were: (a) reporting of complications of at least 50 procedures; (b) differentiation in complications between core biopsy and FNA if both techniques were used; (c) the study was not a subset of patients from other included studies; (d) adequate complication monitoring. Complication monitoring was considered adequate if directly following the procedure a CT scan was acquired, plus a CT scan or chest radiograph 2 to 4 h after the procedure. Studies were excluded during screening if they clearly addressed a different topic, were case reports, conference abstracts, reviews or editorials, or if they were not published in English. A standardized extraction form was used to collect the characteristics of the study regarding patients, nodules, procedures and complications, and how complication monitoring was performed. Two authors (W.H., G.J.) independently extracted these data, with disagreement resolved by consensus. The database was split according to the biopsy method, and all analyses were performed separately for core biopsy and FNA. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale for nonrandomized studies, with results in a score of 0 to 9 [11]. Two authors (W.H., G.J.) independently scored the studies, with disagreement resolved by consensus. Complications were classified as minor or major according to the Society of Interventional Radiology (SIR) Guidelines [12]. Minor complications consisted of pneumothorax without need for intervention, ground glass opacity around the target diagnosed as pulmonary hemorrhage, and transient hemoptysis. Major complications consisted of pneumothorax requiring intervention, hemothorax, air embolism, needle tract seeding, and death. Intervention was defined as treatment consequences (manual aspiration, chest tube placement, or pain control) or hospital admission. For each study the number of (major) complications was determined as the sum of all reported (major) complications. If the complications for different subgroups were reported, the number of (major) complications was determined per subgroup. Study-specific risk factors for overall complications and for major complications that were examined are listed in Table 1. [Table: Study-specific characteristics examined as risk factors for (major) complications] Data analysis Heterogeneity in the overall complication rate between studies was tested and quantified using the I 2 index [13]. I 2 values of 0, 25, 50, and 75 % were defined as no, low, moderate, and high heterogeneity, respectively. To identify sources of heterogeneity, the effect of potential risk factors on between-study heterogeneity was investigated. The R2 equivalent was determined to express the true variance explained by the model, as a proportion of the total true variance. The risk of publication bias was visually assessed with funnel plots of major complication rate against the sample size of the individual studies. Pooled complication rates for core biopsy and FNA were calculated using the random-effects model, weighted by the inverse variance of the studies, under the assumption of heterogeneity. Across subgroups, a common among-study variance component was assumed, and subgroups were

Read the complete text